TIGIT and breast cancer: It is possible that targeting alternative checkpoints such as TIGIT and Tim-3, largely expressed on T cells, as well as therapies against NK cell checkpoints, such as killer cell immunoglobulin-like receptors (KIR; also known as CD158) and NKG2A, will be effective in HR+ breast cancer.